All In Biotech

Drug Trial Radar · NCT06243458

RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

A Phase II, Open-label, Multicenter Study of Orally Administered RVU120 for the Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms (MDS)

Last checked: Nov 19, 2026Latest source record: May 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

41

Actual

Start

Sep 10, 2024

Primary completion

May 2026

Study completion May 2027

Sponsor

Sponsor type
Industry
Collaborators
Universitätsklinikum Leipzig; Saint-Louis Hospital, Paris, France; University of Florence; University of Salamanca; Medical University of Warsaw; Ryvu Therapeutics SA; European Myelodysplastic Neoplasms Cooperative Group
First posted
Feb 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate orally administered RVU120, a novel small molecule Cyclin-dependent Kinase (CDK) 8/19 inhibitor, in terms of erythroid hematologic improvement (HI-E) and safety in participants with lower-risk myelodysplastic syndrome (MDS). Responding patients are eligible to continue treatment until loss of response/disease progression.

Conditions

  • Low Risk Myelodysplastic Syndromes

Interventions

  • RVU120 (SEL120)Drug

    RVU120 will be taken orally every other day (q.o.d). in a 21-day treatment cycle. Doses of RVU120 will be administered from day 1 to day 13 (total of 7 doses per cycle).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Erythroid Response (HI-E) Rate of Participants after Treatment with RVU120 (dose of 150 mg)Time frame: Response Assessment measured after 8 full Cycles of RVU120 administration. Each cycle is 21 days.

Locations

25 sites in 5 countries. Site status is shown where the registry gives one.

  • CHU Grenoble Alpes - Hôpital Michallon

    Grenoble, France

  • CHU de Nice - Hôpital l'Archet 1

    Nice, France

  • Hôpital Saint-Louis, Service d'Hématologie Séniors

    Paris, France

  • CHU de Bordeaux - Centre François Magendie - Groupe Hospitalier Sud

    Pessac, France

  • CHU de Toulouse - Institut Universitaire du Cancer de Toulouse - Oncopole

    Toulouse, France

  • Marien Hospital Düsseldorf

    Düsseldorf, Germany

  • Universität Leipzig, Med. Fak., Klinik und Poliklinik für Hämatologie, Zelltherapie, Hämostaseologie und Infektiologie

    Leipzig, Germany

  • Universitätsklinikum Münster (UKM)

    Münster, Germany

  • AOU delle Marche

    Ancona, Italy

  • AOU Consorziale Policlinico, Università degli Studi Aldo Moro

    Bari, Italy

  • Candiolo Cancer Institute, IRCCS Fondazione del Piemonte per l'Oncologia

    Candiolo, Italy

  • AOU Careggi

    Florence, Italy

  • IRCCS Humanitas Research Hospital

    Milan, Italy

  • Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli

    Reggio Calabria, Italy

  • Samodzielny Publiczny Szpital Kliniczny im.Andrzeja Mielęckiego Śląskiego Uniwersytetu Medycznego w Katowicach

    Katowice, Poland

  • Pratia Hematologia Sp. z o. o. , Pratia Onkologia Katowice

    Katowice, Poland

  • Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M.Kopernika w Łodzi

    Lodz, Poland

  • MTZ Clinical Research powered by Pratia

    Warsaw, Poland

  • Uniwersytecki Szpital Kliniczny im.Jana Mikulacza-Radeckiego

    Wroclaw, Poland

  • Hematology Department Vall d'Hebron Institute of Oncology (VHIO)

    Barcelona, Spain

  • Hospital Universitario de León

    León, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Navarra university clinic

    Pamplona, Spain

  • Complejo Asistencial Universitario de Salamanca

    Salamanca, Spain

  • Hospital Clínico Universitario de Valencia

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.